Download Glycogen Metabolism

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
Glycogen Metabolism
Storage and Mobilization of Glucose
Glycogen Functions
Liver
– Buffer for regulating blood glucose levels
Muscle
– Store of glucose as a fuel for exercise
• high intensity exercise dependent on anaerobic
glycolysis
Glycogen Synthesis
Figure 12-2
Regulation of Glycogen Synthase
Figure 12-4
Active/Inactive
Forms
– Active
• dephosphorylated
– Inactive
• phosphorylated
Regulation of Glycogen Synthase
Fasting
Figure 12-4
Glucagon or
epinephrine
– G-protein
linked
receptors
– increased
[cAMP]
Regulation of Glycogen Synthase
Fasting
Figure 12-4
cAMP activates
Protein Kinase A
Protein kinase A
phosphorylates and
inactivates glycogen
synthase
Little glycogen
synthesis during
fasting
Regulation of Glycogen Synthase
Feeding
Figure 12-4
Insulin
– Reduces [cAMP]
• Stimulates
phosphodiesterase
– Induces and activates
protein
phosphatase-1
• Activates GS
Feeding results in
glycogen synthesis
Glycogen Degradation
Glycogen Phosphorylase
– Hydrolyzes glucose units from glycogen
– Produces glucose-1-P
Removal of branch points
– Debranching enzyme complex
• Glucan transferase
• Alpha-1,6-glucosidase
Regulation of Glycogen Phosphorylase
Fasting
Figure 12-7
Glucagon or
epinephrine
– Increase [cAMP]
– Activates Protein
Kinase A
– Phosphorylates and
activates glycogen
phosphorylase
Fasting results in
increased
glycogenolysis
Regulation of Glycogen Phosphorylase
Feeding
Figure 12-7
Insulin
– Reduces [cAMP]
– Induces and activates
Protein Phosphatase-1
– Inactivates Glycogen
Phosphorylase
Feeding results in
decreased
glycogenolysis
Allosteric Regulation of Glycogen Phosphorylase
Table 12-1
Regulation of Glycogen Degradation during
Exercise
Figure 12-8
Coordinated Regulation of Glycogen Metabolism
(Table 12-2)
Application:
Pharmacological Agents for Diabetics
Insulin
– Mandatory for Type 1 diabetics
– Used in Type 2 diabetics as oral medications
become less effective
Oral medications
– Mechanisms
•
•
•
•
Increase insulin production
Improve insulin receptor sensitivity
Inhibit gluconeogenesis
Inhibit carbohydrate absorption
Sulfonylureas
First widely used diabetic drug
Stimulates endogenous release of insulin from
pancreas
– Direct action on ATP-K channel protein on beta-cells
Short and longer acting forms
– Glipizide (Glucotrol), glyburide (Diabeta), tolazamide
(Tolinase)
Side Effects
– Hypoglycemia
– Weight gain
Meglitinides
Like sulfonylureas, stimulate pancreatic
secretion of insulin
– Short-acting: taken with meals
Replaglinide (Prandin)
Side Effects
– Hypoglycemia
– Weight gain
Biguanides
Mechanism of action
– Reduces gluconeogenesis (stimulates (?) Protein kinase A)
– Decrease absorption of dietary CHO
– Increase insulin sensitivity
Metformin (Glucophage) (most widely used anti-diabetic
drug)
Side effects (not hypoglycemia)
– Lactic acidosis
• Contraindicated in heart failure, liver and kidney disorders
– Diarrhea
Other facts
– Only drug shown to reduced risk diabetes related heart disease
– Derived from French lilac (known as useful for treating symptoms of
diabetes)
Thiazolidinediones (TZDs)
Mechanism of action
– Binds to nuclear receptors that increase transcription of
certain genes
• Decreased insulin resistance
• Leptin levels decreased (increased appetite)
Rosiglitazone (Avandia)
Side effects: edema, risk of hepatitis, increased
heart disease risk (5/07 – FDA safety alert)
Incretin mimetic
Incretins are GI hormones that increase insulin
production
Exenatide (39aa peptide from saliva of gila
monster (lizard spit), synthesized)
– 50% homology with Glugacon-Like Peptide (GLP), an
incretin that stimulates insulin production and inhibits
glucagon production
– Self-regulating: active only when during hyperglycemia
– Appetite suppresent effect: gradual weight loss
Side effects:
– may increase hypoglycemic risk with sulfonylureas
– must be injected 2x per day
Related documents